Metabolic & Cardiometabolic

GLP-1 receptor agonist decreases obesity

Strong support Metabolic & Cardiometabolic

RefutedContestedStrong support

consensus score 1.00

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

15 support 0 contradict 0 tested null 0 mixed · 15 sources, 15 independent groups

What the evidence shows

GLP-1 receptor agonists reduce body weight / adiposity in PCOS (BMI, weight, waist, WHR all significantly lowered).

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2025 · see review Agrees with our grade

Benefit is conditional on continued treatment ('while taking the drug').

“Semaglutide for adults living with obesity (CD015092.pub2). 'Semaglutide results in a clinically relevant weight loss at medium-term follow-up compared to placebo, which is likely to be sustained in the long term, while taking the drug.'”

Why we agree: we reached the same direction independently, from our own appraisal of 15 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (15)

Source	Grade	Stance	Quality	Finding
Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B 2025 · Scientific Reports	meta-analysis	supports	moderate	[FT-verified] Lin2025 meta GLP1RA in PCOS: reduced BMI/wt/WC; niche population; vault sources narrower than STEP/SURMOUNT
Rajamoorthi A et al 2026 · bioRxiv	animal	supports	moderate	Mouse model of maternal obesity; semaglutide administered preconception through lactation improved body composition and glucose metabolism in HFD-fed dams, persisting 10 weeks post-discontinuation.
Damen 2026 · Ann Intern Med	meta-analysis	supports	high	Living network MA (69 studies, >112k): semaglutide and tirzepatide produced greatest weight loss
Parlati AL et al 2026 · study_type: observational	observational	supports	moderate	Narrative review of tirzepatide cardiometabolic evidence; cites SURMOUNT trials showing marked and durable weight reduction with improvements in waist circumference, BP, triglycerides in obesity.
Elkind-Hirsch K, et al. 2022 · Fertil Steril	RCT	supports	moderate	[FT-verified] Elkind-Hirsch2022 liraglutide3mg PCOS n=82 dbl-blind wt loss vs placebo; PCOS-specific not general-obesity landmark
Zaman W et al 2026 · study_type: observational	observational	supports	moderate	Narrative review of orforglipron (oral GLP-1RA) for obesity pharmacotherapy; concludes clinically meaningful weight reduction demonstrated, though comparative efficacy vs injectables uncertain.
Zhang Y et al 2026 · study_type: animal	animal	supports	moderate	DIO mouse study of engineered GLP-1R/GIPR agonist molecules; sequential dual-agonist-to-antagonist molecule produced 21.59% body weight reduction vs 14.5% for comparator (p<0.001).
Dubin RL et al 2026 · study_type: observational	observational	supports	moderate	Updated narrative review of 40 DXA-based body-composition reports on GLP-1RA-based agents; mean %FFML (fat-free mass loss) 29.1%, confirming substantial concurrent weight/fat loss with treatment.
Castro-Gamboa J et al 2026 · study_type: observational	observational	supports	moderate	Narrative review comparing orforglipron to marketed GLP-1RA benchmarks (dulaglutide, oral/injectable semaglutide) for obesity and T2D; synthesizes comparative weight-loss efficacy evidence, though indirect comparisons are limited.
Li Y et al 2026 · study_type: meta-analysis	meta-analysis	supports	high	Network meta-analysis of 17 RCTs (n=1230) in adolescents with overweight/obesity; semaglutide 2.4mg SC gave largest body weight reduction (MD -18.00kg, 95% CrI -24.34 to -11.69, high confidence) and BMI reduction.
Hamarsheh 2026 · Endocrinol Diabetes Metab	meta-analysis	supports	moderate	Network MA 25 RCTs: tirzepatide 15mg -17.97% and semaglutide 7.2mg -14.66% body weight
Damhof MA et al 2026 · study_type: observational	observational	supports	moderate	Review on weight regain after GLP-1RA discontinuation; explicitly states GLP-1RAs 'produce substantial and sustained weight loss during active treatment,' with regain occurring only after cessation.
Abid M et al 2026 · study_type: observational	observational	supports	moderate	Narrative review of GLP-1RAs in adolescent obesity; cites STEP TEENS trial showing ~16% mean body weight reduction over 68 weeks with once-weekly semaglutide, with liraglutide producing more modest reductions.
Bruna-Mejias A et al 2026 · study_type: meta-analysis	meta-analysis	supports	moderate	PROSPERO-registered systematic review and meta-analysis (35 parent trials) of GLP-1RA/incretin therapies within lifestyle interventions in adults with overweight/obesity; MD -10.08 kg (95% CI -12.76 to -7.39) vs placebo/control, also -9.53
Babazadeh D et al 2026 · study_type: observational	observational	supports	moderate	Prospective observational CRAVE study (n=28) of adults with obesity on semaglutide/tirzepatide for 24 weeks; significant reductions in body weight and adiposity (all P<0.001), alongside skeletal muscle mass loss.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.